
Meta-regression coefficients, by drug class, S4 - FDA approval/ not in market
======================================================================================
                      Outcome               Class    Slope    CI.lb    CI.ub   P-value
--------------------------------------------------------------------------------------
5               All-cause Mortality        GLP-1RA    0.53    -4.79     5.84    0.85  
1            Cardiovascular Mortality      GLP-1RA   -0.12    -5.32     5.08    0.96  
2                      MACE                GLP-1RA    2.02    -3.34     7.38    0.46  
6              Myocardial Infarction       GLP-1RA    0.3     -5.38     5.97    0.92  
7                     Stroke               GLP-1RA    1.8     -3.14     6.75    0.47  
3        Hospitalization for Heart Failure GLP-1RA    -0.4    -5.38     4.58    0.87  
4             Composite Renal Outcome      GLP-1RA    3.56    -5.07    12.19    0.42  
12              All-cause Mortality         SGLT2i   -0.33    -0.89     0.23    0.25  
8            Cardiovascular Mortality       SGLT2i   -0.54    -1.12     0.05    0.07  
9                      MACE                 SGLT2i   -1.15    -3.46     1.16    0.33  
13             Myocardial Infarction        SGLT2i    0.15    -2.49     2.78    0.91  
14                    Stroke                SGLT2i    0.08    -2.75     2.91    0.96  
10       Hospitalization for Heart Failure  SGLT2i   -1.44    -1.84    -1.05      0   
11            Composite Renal Outcome       SGLT2i   -0.29      -1      0.41    0.41  
--------------------------------------------------------------------------------------
Absolute risk difference and baseline cardiovascular mortality rate. Sensitivity      
